Peter Grondziowski
Endocrinology, Diabetes & Metabolism · Pittsburgh, PANPI 1447250469
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $122,426 of the $142,961 with a category attached, or 85.6%. Novo Nordisk accounts for 94.4% of it on its own, with 25 other manufacturers making up the rest. Reporting peaked in 2019 at $57,745 and has fallen 98.0% since, to $1,171 in 2025. Among endocrinology, diabetes & metabolism clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 516 payments — averaging $277.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$135K
- Lilly USA, LLC$1K
- Esperion Therapeutics, Inc.$729
- Sanofi-aventis U.S. LLC$725
- Amgen$705
- Boehringer Ingelheim$661
- plus $4K from 20 others
What the payments were for
- Consulting fees$1,4851%
- Speaking & faculty fees$122,42686%
- Travel & lodging$8,1606%
- Food & beverage$10,7928%
- Education$990%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 228 | $134,991 |
| Lilly USA, LLC | 73 | $1,269 |
| Esperion Therapeutics, Inc. | 14 | $729 |
| Sanofi-aventis U.S. LLC | 28 | $725 |
| Amgen | 8 | $705 |
| Boehringer Ingelheim | 15 | $661 |
| Dexcom, Inc. | 20 | $639 |
| Bayer | 25 | $637 |
| AbbVie(2 entities) | 26 | $559 |
| AstraZeneca(2 entities) | 20 | $498 |
| Tandem Diabetes Care, Inc. | 8 | $412 |
| Amneal Pharmaceuticals LLC | 19 | $355 |
| Corcept Therapeutics | 5 | $162 |
| Madrigal Pharmaceuticals | 1 | $139 |
| Mannkind Corporation | 6 | $85 |
| Ascendis Pharma Endocrinology Inc | 3 | $58 |
| Rhythm Pharmaceuticals, Inc. | 2 | $54 |
| Xeris Pharmaceuticals, Inc. | 3 | $51 |
| IBSA Pharma Inc. | 2 | $43 |
| Pfizer | 2 | $43 |
| Abbott | 2 | $35 |
| Cequr Corporation | 1 | $29 |
| Sun Pharmaceutical Industries Inc. | 2 | $27 |
| Antares Pharma, Inc. | 1 | $21 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Currax Pharmaceuticals LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$68,025
- RYBELSUS$41,302
- Tresiba$15,135
- Xultophy 100/3.6$3,510
- Victoza$1,485
- NEXLIZET$590
- NEXLETOL$590
- Repatha$573
- JARDIANCE$468
- DEXCOM G7 GSS (161)$275
- REZDIFFRA$139
- t:slim X2 Insulin Pump with Control-IQ$125
- Kerendia$122
- DEXCOM G6 TRANSMITTER$117
How this compares
$142,961 in reported general payments places this provider in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
See all endocrinology, diabetes & metabolism providers in Pennsylvania →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 46 | $89,564 |
| Tresiba Flextouch U-200Insulin Degludec | 37 | $46,335 |
| JardianceEmpagliflozin | 35 | $44,971 |
| FarxigaDapagliflozin Propanediol | 24 | $27,061 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 13 | $8,031 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 13 | $7,365 |
| SynthroidLevothyroxine Sodium | 66 | $6,188 |
| Repatha SyringeEvolocumab | 11 | $6,074 |
| Humalog Kwikpen U-100Insulin Lispro | 12 | $5,834 |
| NovologInsulin Aspart | 19 | $1,917 |
| Ultra-Fine Mini Pen NeedlePen Needle, Diabetic | 15 | $1,503 |
| Hydrocortisone | 17 | $1,060 |
| Metformin Hcl | 82 | $838 |
| Irbesartan | 31 | $708 |
| Rosuvastatin Calcium | 52 | $485 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $134,991 | $91,48165 claims |
| Boehringer IngelheimJardiance | $661 | $44,97135 claims |
| AstraZenecaFarxiga | $498 | $27,06124 claims |
| AbbVieSynthroid | $559 | $6,18866 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $355 | $38340 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 388 endocrinology, diabetes & metabolism providers in Pennsylvania.
Other endocrinology, diabetes & metabolism in Pittsburgh
- Vijay BahlPittsburgh$998K
- Swarna VarmaPittsburgh$520K
- Sachin BahlPittsburgh$162K
- Patricia BononiPittsburgh$91K
- Murray GordonPittsburgh$60K
- Frederico ToledoPittsburgh$50K
- Hugo LinPittsburgh$21K
- Pouneh FazeliPittsburgh$20K
- Serge JabbourPhiladelphia$1.2M
- Geraldo SaavedraWhitehall$698K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.